Last updated: February 19, 2026
Eurasian Patent Office (EAPO) biopharmaceutical patents offer a complex but potentially lucrative landscape for innovators. Key considerations for patentability involve demonstrating novelty, inventive step, and industrial applicability, with specific emphasis on therapeutic efficacy and methods of treatment. Enforceability hinges on clear claim construction and robust evidence of infringement, while claim scope significantly impacts market exclusivity and competitive positioning. The EAPO's examination process and legal framework require meticulous attention to detail for successful patent prosecution and enforcement.
What Are the Core Patentability Requirements for Biopharmaceutical Inventions at the EAPO?
The Eurasian Patent Convention (EPC) outlines three fundamental requirements for patentability: novelty, inventive step, and industrial applicability [1]. For biopharmaceutical inventions, these requirements are applied with specific considerations.
Novelty
An invention is considered novel if it has not been made public prior to the filing date of the patent application. This includes disclosures in written publications, oral presentations, public use, or any other means worldwide. For biopharmaceuticals, this means that the specific gene sequence, protein, antibody, or therapeutic compound must not have been previously disclosed in a way that would enable a person skilled in the art to reproduce it.
- Example: Discovery of a novel protein with a specific therapeutic function, where neither the protein sequence nor its function was previously known, meets the novelty requirement. A previously known protein with a newly discovered therapeutic use may also be patentable, depending on inventive step.
Inventive Step
Inventive step, often referred to as non-obviousness, requires that the invention is not obvious to a person skilled in the relevant technical field, considering the state of the art at the filing date. For biopharmaceuticals, this often involves demonstrating that the claimed invention provides an unexpected technical effect or solves a technical problem that was not readily apparent.
- Key considerations for inventive step in biopharmaceuticals:
- Unexpected Efficacy: A new formulation or dosage of a known drug that provides significantly improved therapeutic results compared to existing treatments.
- New Mechanism of Action: A compound that acts via a previously unknown biological pathway to achieve a therapeutic effect.
- Overcoming Technical Challenges: A novel delivery system for a biologic that improves stability or bioavailability, solving known limitations.
- New Therapeutic Indication: Discovering a novel use for a known compound, provided this use was not suggested by the prior art and offers a technical advantage.
Industrial Applicability
The invention must be capable of being made or used in any kind of industry, including agriculture. For biopharmaceuticals, this is generally met if the claimed compound can be synthesized or produced, or if the claimed method of treatment can be applied.
- Specific applications: This includes diagnostic methods, production processes for biologics, and therapeutic uses of compounds.
How Does the EAPO Examine Therapeutic Methods and Diagnostic Procedures?
The EAPO's approach to patenting medical treatments and diagnostics is crucial for biopharmaceutical innovation.
Patentability of Therapeutic Methods
Under Article 4 of the Eurasian Patent Convention, methods for treatment of the human or animal body by surgery or therapy and diagnostic methods practiced on the human or animal body are not considered inventions for the purposes of patentability [1]. However, products, in particular substances or compositions, for use in any of these methods are patentable.
- First Medical Use Claims: A compound previously known for one therapeutic use is patentable for a new therapeutic use. This is often formulated as "Substance X for use in treating disease Y."
- Second and Subsequent Medical Use Claims: Similar to first medical use, further uses of already known compounds are patentable. These are also formulated as "Substance X for use in treating disease Y."
- Methods of Treatment vs. Products for Use: While a direct method of treatment claim (e.g., "A method of treating disease X comprising administering dose Y of substance Z") is not patentable, a claim directed to the product for use in that method is. This distinction is critical for securing protection.
Patentability of Diagnostic Methods
Similar to therapeutic methods, diagnostic methods practiced on the human or animal body are generally excluded from patentability. However, diagnostic products or kits designed for use in such methods are patentable.
- Example: A kit comprising specific antibodies and reagents for detecting a biomarker indicative of a disease is patentable. A method of diagnosis using this kit, however, would not be.
- Exclusions: Methods of diagnosis that are purely intellectual or administrative are not excluded from patentability if they meet the general criteria.
What Are the Key Challenges and Strategies for Claim Drafting in EAPO Biopharmaceutical Patents?
Effective claim drafting is paramount for securing broad and enforceable patent protection.
Claim Types and Their Scope
The EAPO recognizes various claim types, with distinct implications for scope and enforceability.
- Product Claims: These claims define the claimed invention by its chemical structure, composition, or physical characteristics. They typically offer the broadest scope of protection.
- Chemical Compounds: Claims directed to specific molecules or classes of molecules.
- Biologics: Claims covering specific protein sequences, antibodies (e.g., by epitope binding or sequence identity), or nucleic acids.
- Formulations: Claims directed to specific mixtures of active ingredients and excipients.
- Process Claims: These claims define the method of producing a product. They protect the manufacturing process but not the product itself if it can be made by a different process.
- Use Claims: As discussed, these are critical for biopharmaceuticals, protecting the use of a known or novel product for a specific therapeutic or diagnostic purpose.
- First Medical Use: Claimed as "Substance X for use as a medicament."
- Subsequent Medical Use: Claimed as "Substance X for use in treating disease Y."
Strategies for Broad Claim Scope
- Broad Markush Claims: For chemical compounds, employing Markush (generic) structures allows for the protection of a genus of related compounds by defining variable substituents and their possible alternatives. Careful drafting is required to ensure sufficiency of disclosure and avoid lack of novelty or inventive step over the prior art.
- Functional Claims for Biologics: Claims defining antibodies by their function, such as binding to a specific epitope or neutralizing a particular target, can offer broader protection than claims based solely on sequence identity. However, these require clear and reproducible functional definitions.
- Covering Polymorphs and Salts: For small molecules, claims can be drafted to cover specific crystalline forms (polymorphs) or pharmaceutically acceptable salts to broaden protection against generic competitors who might develop alternative forms.
- Enantiomerically Pure Claims: If a racemic mixture is known but an enantiomerically pure form provides a significant therapeutic advantage, claims can be directed to the pure enantiomer.
Sufficiency of Disclosure
The patent application must disclose the invention in a manner sufficiently clear and complete for a person skilled in the art to carry it out. For biopharmaceuticals, this often means providing detailed biological data, sequence information, manufacturing protocols, and evidence of therapeutic efficacy.
- Deposit of Biological Material: In cases where a claimed microorganism or cell line is not readily available or reproducible from the description, deposit with an internationally recognized depository (e.g., under the Budapest Treaty) may be required.
How is Patent Infringement Assessed and Enforced at the EAPO?
Enforcement of biopharmaceutical patents in EAPO member states requires a thorough understanding of infringement principles and available remedies.
Defining Infringement
Infringement occurs when a third party makes, uses, offers for sale, sells, or imports a patented invention without the patent holder's authorization within the territory of an EAPO member state that has granted a national patent based on the Eurasian patent.
- Direct Infringement: This occurs when a third party directly practices any element of a patented claim. For example, selling a patented drug or using a patented diagnostic method.
- Indirect Infringement (Contributory Infringement): While not as explicitly defined in all EAPO member states as in some other jurisdictions, indirect infringement can arise when a party supplies essential components for practicing a patented invention, knowing that these components are specifically adapted for such use and are not staple commercial items.
- Doctrine of Equivalents: While not always explicitly codified, many EAPO member states apply a doctrine of equivalents, allowing for finding infringement even if the infringing product or process does not precisely fall within the literal scope of the claims, but performs substantially the same function, in substantially the same way, to achieve substantially the same result.
Specific Considerations for Biopharmaceuticals
- Process Patents: Proving infringement of a process patent can be challenging, especially if the infringing process is not visible from the final product. EAPO member states often have provisions that shift the burden of proof to the alleged infringer in certain circumstances, particularly when a new product is made by a patented process.
- Use Patents: Enforcement of "use" claims requires demonstrating that the alleged infringer is inducing or authorizing others to use the patented method or is marketing their product for a patented use. This can involve market analysis and monitoring of promotional materials.
- Antibody Patents: Infringement analysis often involves comparing the binding characteristics (e.g., epitope mapping, affinity) of the accused antibody to the claimed antibody. Sequence identity is also a key factor, but functional equivalence can also be considered.
Remedies for Infringement
Upon successful action for infringement, patent holders may be entitled to:
- Injunctions: Court orders prohibiting the infringing activity.
- Damages: Monetary compensation for losses incurred due to infringement. This can include lost profits or a reasonable royalty.
- Seizure and Destruction: Order for infringing products to be seized and destroyed.
What is the EAPO's Position on Patent Term Extension (PTE) or Supplementary Protection Certificates (SPCs)?
The EAPO itself does not offer Patent Term Extension or Supplementary Protection Certificates. However, EAPO member states that have national patent laws implementing these provisions may grant them on the basis of the national validation of a Eurasian patent.
- EAPO Patent Scope: A Eurasian patent is a single patent that is validated in designated member states, resulting in a bundle of national patents. The EAPO examination process is centralized, but national validation and post-grant procedures, including PTE/SPC, are governed by the laws of individual member states.
- Member State Specifics: Innovators must consult the specific laws of each EAPO member state where they intend to seek PTE or SPCs. Requirements and eligibility criteria vary significantly. Generally, these provisions aim to compensate for the time lost during the regulatory approval process (e.g., for marketing authorization of medicinal products) that delays the effective market exclusivity period.
What is the Impact of Data Exclusivity on Biopharmaceutical Patents in EAPO Member States?
Data exclusivity is a separate regulatory protection that operates alongside patent protection. It prevents regulatory authorities from relying on the innovator's preclinical and clinical data to approve generic or biosimilar versions of a drug for a specified period.
- EAPO States and Data Exclusivity: The availability and duration of data exclusivity vary by EAPO member state. Some states may have established data exclusivity provisions, while others may not.
- Relationship with Patents: Data exclusivity is distinct from patent rights. A patent grants the right to exclude others from making, using, or selling the patented invention. Data exclusivity prevents regulatory approval of generics based on the innovator's data, irrespective of patent status.
- Strategic Importance: Both patent protection and data exclusivity are crucial for maximizing market exclusivity for biopharmaceutical products. Innovators must strategically plan for both to ensure comprehensive market protection.
Key Takeaways
Eurasian Patent Office biopharmaceutical patent applications require strict adherence to novelty, inventive step, and industrial applicability criteria, with particular attention to the demonstration of therapeutic efficacy. Therapeutic methods are not directly patentable, but products for use in such methods are, necessitating precise claim drafting. Enforceability relies on clear claim construction, evidence of infringement, and understanding of remedies available in member states. Patent term extensions and data exclusivity are governed by national laws of validated member states, not the EAPO itself, and are critical for maximizing market exclusivity.
FAQs
-
Can a newly discovered therapeutic use for an existing drug be patented in EAPO member states?
Yes, provided the new use was not obvious from the prior art and offers a technical advantage. Claims are typically drafted as "substance X for use in treating disease Y."
-
What is the main difference between a patentable invention and a method of treatment at the EAPO?
Methods of treating the human or animal body by therapy or surgery are not patentable per se. However, any product (substance or composition) for use in such a method is patentable.
-
How can I ensure broad protection for my antibody invention at the EAPO?
Consider drafting claims that cover not only sequence identity but also functional characteristics, such as binding to a specific epitope or neutralizing a particular target.
-
Does a granted Eurasian patent provide automatic protection in all EAPO member states?
No, a Eurasian patent must be validated in designated member states according to their national procedures and language requirements to have legal effect in those countries.
-
Is data exclusivity protection available in all EAPO member states for biopharmaceuticals?
Data exclusivity provisions and their duration vary significantly among EAPO member states. Innovators must review the specific regulations of each country where market approval is sought.
Citations
[1] Eurasian Patent Convention. (n.d.). The Eurasian Patent Convention. Eurasian Patent Organization. Retrieved from https://www.eapo.org/en/convention/
